---
title: "OSE Immunotherapeutics is focusing on advancing late stage value drivers Lusvertikimab and Tedopi with strategic refocusing."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277501599.md"
description: "OSE Immunotherapeutics is strategically refocusing on advancing its late-stage value drivers, Lusvertikimab and Tedopi®. This decision highlights the company's commitment to maximizing these key assets, which are in advanced development stages and crucial for enhancing shareholder value. The realignment aims to streamline focus and allocate resources efficiently, positioning Lusvertikimab and Tedopi® as significant growth opportunities within OSE Immunotherapeutics' portfolio."
datetime: "2026-03-02T17:01:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277501599.md)
  - [en](https://longbridge.com/en/news/277501599.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277501599.md)
---

# OSE Immunotherapeutics is focusing on advancing late stage value drivers Lusvertikimab and Tedopi with strategic refocusing.

OSE Immunotherapeutics is ramping up its strategic realignment to progress its late-stage value drivers, Lusvertikimab and Tedopi®. These key assets are currently at advanced stages of development and hold significant promise for the company. The decision to prioritize these programs underscores OSE Immunotherapeutics' commitment to maximizing their potential and enhancing shareholder value. This move comes as part of the company's overarching efforts to streamline its focus and allocate resources efficiently. Lusvertikimab and Tedopi® represent important pillars in OSE Immunotherapeutics' portfolio, with substantial opportunities for growth and success.

### Related Stocks

- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IPA.US](https://longbridge.com/en/quote/IPA.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [LYEL.US](https://longbridge.com/en/quote/LYEL.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [MLTX.US](https://longbridge.com/en/quote/MLTX.US.md)

## Related News & Research

- [MoonLake Immunotherapeutics CSO Kristian Reich disposes of $1 million in common shares](https://longbridge.com/en/news/293660700.md)
- [HEDGE FLOW-Hedge fund bets on rising US healthcare stocks near 5-year high, Goldman says](https://longbridge.com/en/news/293938581.md)
- [MoonLake Immunotherapeutics CSO Kristian Reich sells 43,700 shares for $877,933](https://longbridge.com/en/news/293391282.md)
- [Trump Says US To Exempt Import Tariff On Generic Drugs For Two Years](https://longbridge.com/en/news/293481843.md)
- [Generic drug sector seeks policy fixes after Trump tariff threat](https://longbridge.com/en/news/293501714.md)